Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Atreca, Inc. (BCEL)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
3 days ago | GlobeNewsWire
a week ago | GlobeNewsWire
2 weeks ago | Pulse2
2 weeks ago | GlobeNewsWire
3 weeks ago | GlobeNewsWire
3 months ago | GlobeNewsWire
5 months ago | GlobeNewsWire
Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments
5 months ago | GlobeNewsWire
5 months ago | GlobeNewsWire
9 months ago | GlobeNewsWire